Search - tctmd.com

Displaying 1 - 20 of 21

Sort: Relevancy | Date

Patients With Obesity Get Biggest Benefit from Evolocumab: FOURIER

News Daily News

Patients With Obesity Get Biggest Benefit from Evolocumab: FOURIER

Michael O'Riordan

December 12, 2025

SELECT: Semaglutide Cuts CV Events in Adults With Overweight or Obesity

News Daily News

SELECT: Semaglutide Cuts CV Events in Adults With Overweight or Obesity

August 08, 2023

Oral PCSK9 Inhibitor Reduces LDL Cholesterol in Phase IIb Study

News Conference News ACC 2023

Oral PCSK9 Inhibitor Reduces LDL Cholesterol in Phase IIb Study

March 10, 2023

Making the Case for Sex-Specific CVD Guidelines

News Daily News

Making the Case for Sex-Specific CVD Guidelines

July 08, 2021

Even Low-Dose Steroids Increase the Risk of CVD

News Daily News

Even Low-Dose Steroids Increase the Risk of CVD

Michael O'Riordan

December 03, 2020

Colchicine in the Crosshairs for Its High US Cost

News Daily News

Colchicine in the Crosshairs for Its High US Cost

December 01, 2020

Rilonacept Prevents Recurrent Pericarditis: RHAPSODY

News Conference News AHA 2020

Rilonacept Prevents Recurrent Pericarditis: RHAPSODY

November 17, 2020

NSAIDs Boost CV, Bleeding Risks in Post-MI Patients

News Daily News

NSAIDs Boost CV, Bleeding Risks in Post-MI Patients

July 28, 2020

Signal of Aortic Stenosis Risk With Celecoxib

News Daily News

Signal of Aortic Stenosis Risk With Celecoxib

Michael O'Riordan

March 05, 2019

FDA Adds Boxed Warning About CV Risks to Gout Drug Febuxostat

News Daily News

FDA Adds Boxed Warning About CV Risks to Gout Drug Febuxostat

February 22, 2019

Hopes Fade for a CV Indication for Canakinumab: What’s Next for the Inflammatory Hypothesis?

News Features

Hopes Fade for a CV Indication for Canakinumab: What’s Next for the Inflammatory Hypothesis?

Michael O'Riordan

February 01, 2019

Canakinumab Reduces Heart-Failure Hospitalizations Among Responders: CANTOS Subanalysis

News Conference News AHA 2018

Canakinumab Reduces Heart-Failure Hospitalizations Among Responders: CANTOS Subanalysis

November 13, 2018

Methotrexate, an Anti-inflammatory, Fails to Lower Risk of Cardiovascular Events: CIRT

News Conference News AHA 2018

Methotrexate, an Anti-inflammatory, Fails to Lower Risk of Cardiovascular Events: CIRT

Michael O'Riordan

November 10, 2018

FDA Puts the Kibosh on Canakinumab for Cardiac Indication—at Least for Now

News Daily News

FDA Puts the Kibosh on Canakinumab for Cardiac Indication—at Least for Now

Michael O'Riordan

November 01, 2018

NSAIDs Account for Large Part of Osteoarthritis-CVD Link, Study Suggests

News Daily News

NSAIDs Account for Large Part of Osteoarthritis-CVD Link, Study Suggests

June 21, 2018

All-Cause Death Not Increased With Febuxostat Among Medicare Patients With Gout

News Daily News

All-Cause Death Not Increased With Febuxostat Among Medicare Patients With Gout

June 19, 2018

FDA Advisory Panel Says Celecoxib Is as Safe for Heart as Ibuprofen and Naproxen

News Daily News

FDA Advisory Panel Says Celecoxib Is as Safe for Heart as Ibuprofen and Naproxen

Michael O'Riordan

April 25, 2018

FDA Advisors Take Fresh Look at Celecoxib Safety as PRECISION Aspirin Analysis Unveiled

News Daily News

FDA Advisors Take Fresh Look at Celecoxib Safety as PRECISION Aspirin Analysis Unveiled

Michael O'Riordan

April 24, 2018

Differential Blood Pressure Effects of Ibuprofen, Naproxen, and Celecoxib in Patients with Arthritis

Presentation

Differential Blood Pressure Effects of Ibuprofen, Naproxen, and Celecoxib in Patients with Arthritis

August 30, 2017

News Conference News AHA 2016

No CV Safety Differences for COX-2 Inhibitor vs Other NSAIDs in PRECISION

November 13, 2016

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.